Here's where aggressive traders could go long BMRN.
I'm not saying get married to the stock, I'm saying that the idea could be a trade based on two possible catalysts.
Here's what traders can do.
Pfizer attributed the quarter's sales of Comirnaty, the firm's Covid-19 Messenger RNA vaccine, for the size of the top and bottom line beats.
There are reasons to believe the shares of Dynavax Technologies and Eyenovia Inc. could do well in the months ahead.
The lack of urgency at the FDA, as it is in the defense space, is alarming.
A recent trio of acquisition deals indicates the doldrums in the sector may be over.
Investors are using the available weakness to buy the stock.
Plus, Zscaler largely delivers for its owners with its latest results.